Affordable Access

deepdyve-link
Publisher Website

Bevacizumab for the management of diabetic macular edema.

Authors
  • Stefanini, Francisco Rosa1
  • Arevalo, J Fernando
  • Maia, Maurício
  • 1 Francisco Rosa Stefanini, Maurício Maia, The Retina Division, Ophthalmology Department, Federal University of São Paulo, São Paulo, SP 04023-062, Brazil. , (Brazil)
Type
Published Article
Journal
World Journal of Diabetes
Publisher
Baishideng Publishing Group Co (World Journal of Diabetes)
Publication Date
Apr 15, 2013
Volume
4
Issue
2
Pages
19–26
Identifiers
DOI: 10.4239/wjd.v4.i2.19
PMID: 23593532
Source
Medline
Keywords
License
Unknown

Abstract

Diabetic retinopathy (DR) is a leading cause of vision loss in the working-age population and is relatedto 1%-5% of cases of blindness worldwide. Diabetic macular edema (DME) is the most frequent cause of DR vision loss and is an important public health problem. Recent studies have implicated vascular endothelial growth factor (VEGF) in DR and DME pathogenesis, as well as provided evidence of the benefits of anti-VEGF agents for the management of such conditions. Despite the benefits of intravitreal ranibizumab injection for the management of DME, the cost-effectiveness of intravitreal bevacizumab therapy has gained increasing interest in the scientific community. This review summarizes the studies examining bevacizumab for the management of DME, focusing on the efficacy and duration of the clinical benefits of decreasing DME and the improvement of best-corrected visual acuity (BCVA). There is strong evidence that intravitreal bevacizumab injection therapy has a good cost-effective profile in the management of DME and may be associated with laser photocoagulation; however, its clinical superiority in terms of the duration of DME regression and the improvement of BCVA compared with intravitreal ranibizumab and other intravitreal anti-VEGF therapies remains unclear and deserves further investigation.

Report this publication

Statistics

Seen <100 times